Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanomaAlice Indini, Michele Del Vecchio, Lorenza Di Guardo et al.|Journal of Cancer Research and Clinical Oncology|2018Cited by 200
Circulating Tumor DNA as a Marker of Minimal Residual Disease After Radical Resection of Colorectal Liver MetastasesFederica Marmorino, Chiara Cremolini, Michele Prisciandaro et al.|JCO Precision Oncology|2022Cited by 28
Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experienceCarolina Cimminiello, Michele Del Vecchio, Lorenza Di Guardo et al.|Melanoma Research|2018Cited by 6
Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanomaAlice Indini, Michele Del Vecchio, Lorenza Di Guardo et al.|Tumori Journal|2019Cited by 6
A randomized phase III study of fractionated docetaxel, oxaliplatin, capecitabine (low-tox) vs epirubicin, oxaliplatin and capecitabine (eox) in patients with locally advanced unresectable or metastatic gastric cancer: the lega trialGerardo Rosati, Roberto Labianca, Chiara Alessandra Cella et al.|Gastric Cancer|2022Cited by 4